文献速递流行病学与生物统计基础与转化研究

基因代理的PCSK9抑制与前列腺癌风险的关联:一项孟德尔随机化研究

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
PubMed 文献 · PLoS Med · 2023-01-03

本研究采用药物靶点孟德尔随机化分析,评估基因代理的HMGCR、NPC1L1和PCSK9抑制对前列腺癌风险的影响。结果显示,基因代理的PCSK9抑制(相当于LDL-c降低1个标准差)与总体前列腺癌风险降低相关(OR=0.85,95%CI 0.76-0.96),并与早发性前列腺癌风险降低相关(OR=0.70,95%CI 0.52-0.95)。基因代理的HMGCR抑制和NPC1L1抑制与前列腺癌风险的关联未达统计学显著。

要点

  • 基因代理的PCSK9抑制与总体前列腺癌风险降低相关(OR=0.85,95%CI 0.76-0.96)。
  • 基因代理的PCSK9抑制与早发性前列腺癌风险降低相关(OR=0.70,95%CI 0.52-0.95)。
  • 基因代理的HMGCR和NPC1L1抑制与前列腺癌风险的关联未达统计学显著。

核心结论

  • 研究支持基因代理的PCSK9抑制与总体和早发性前列腺癌风险降低之间存在强关联,可能通过独立于LDL-c靶向效应的替代机制。
  • 需要进一步临床研究证据来确认该发现以及Lp(a)的潜在中介作用。

研究设计与样本

  • 药物靶点孟德尔随机化研究,使用来自全球脂质遗传学联盟GWAS(N=1,320,016)中与LDL-c相关的SNPs(P<5×10-8)作为HMGCR、NPC1L1和PCSK9基因治疗性抑制的代理。
  • 前列腺癌风险数据来自PRACTICAL联盟,采用两样本孟德尔随机化逆方差加权法分析。
  • 验证分析使用欧洲 ancestry 男性UK Biobank参与者LDL-c GWAS(N=201,678)的遗传工具,以及基于肝脏来源基因表达和循环血浆靶蛋白水平的工具。

主要发现

  • 基因代理的PCSK9抑制(相当于LDL-c降低1个标准差)与总体前列腺癌风险降低相关(OR=0.85,95%CI 0.76-0.96,P=9.15×10-3)。
  • 基因代理的PCSK9抑制与早发性前列腺癌风险降低相关(OR=0.70,95%CI 0.52-0.95,P=0.023)。
  • 基因代理的HMGCR抑制对前列腺癌风险的效应估计相似但95%CI更宽(OR=0.83,95%CI 0.62-1.13,P=0.244),基因代理的NPC1L1抑制与前列腺癌风险升高相关但95%CI包含无效值(OR=1.34,95%CI 0.87-2.04,P=0.180)。
  • 肝脏特异性PCSK9表达(每标准差PCSK9表达降低OR=0.90,95%CI 0.86-0.95,P=5.50×10-5)和循环血浆PCSK9蛋白水平(每标准差PCSK9蛋白水平降低OR=0.93,95%CI 0.87-0.997,P=0.04)的基因代理效应与前列腺癌风险相关。
  • 共定位分析发现肝脏来源PCSK9表达与前列腺癌风险共享遗传变异rs553741的强证据(PPA=81.3%),而HMGCR(PPA=0.33%)和NPC1L1表达(PPA=0.38%)证据弱;基因代理的PCSK9抑制与Lp(a)水平强相关(Beta=-0.08,95%CI -0.12至-0.05,P=1.00×10-5),但与BMI或睾酮无关。

局限性

  • 估计基于终生暴露,使得与试验结果的直接比较具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding factors. In this study, we performed a drug target Mendelian randomisation (MR) analysis to evaluate the association of genetically proxied inhibition of LDL-c-lowering drug targets on risk of PrCa. METHODS AND FINDINGS: Single-nucleotide polymorphisms (SNPs) associated with LDL-c (P < 5 × 10-8) from the Global Lipids Genetics Consortium genome-wide association study (GWAS) (N = 1,320,016) and located in and around the HMGCR, NPC1L1, and PCSK9 genes were used to proxy the therapeutic inhibition of these targets. Summary-level data regarding the risk of total, advanced, and early-onset PrCa were obtained from the PRACTICAL consortium. Validation analyses were performed using genetic instruments from an LDL-c GWAS conducted on male UK Biobank participants of European ancestry (N = 201,678), as well as instruments selected based on liver-derived gene expression and circulation plasma levels of targets. We also investigated whether putative mediators may play a role in findings for traits previously implicated in PrCa risk (i.e., lipoprotein a (Lp(a)), body mass index (BMI), and testosterone). Applying two-sample MR using the inverse-variance weighted approach provided strong evidence supporting an effect of genetically proxied inhibition of PCSK9 (equivalent to a standard deviation (SD) reduction in LDL-c) on lower risk of total PrCa (odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.76 to 0.96, P = 9.15 × 10-3) and early-onset PrCa (OR = 0.70, 95% CI = 0.52 to 0.95, P = 0.023). Genetically proxied HMGCR inhibition provided a similar central effect estimate on PrCa risk, although with a wider 95% CI (OR = 0.83, 95% CI = 0.62 to 1.13, P = 0.244), whereas genetically proxied NPC1L1 inhibition had an effect on higher PrCa risk with a 95% CI that likewise included the null (OR = 1.34, 95% CI = 0.87 to 2.04, P = 0.180). Analyses using male-stratified instruments provided consistent results. Secondary MR analyses supported a genetically proxied effect of liver-specific PCSK9 expression (OR = 0.90 per SD reduction in PCSK9 expression, 95% CI = 0.86 to 0.95, P = 5.50 × 10-5) and circulating plasma levels of PCSK9 (OR = 0.93 per SD reduction in PCSK9 protein levels, 95% CI = 0.87 to 0.997, P = 0.04) on PrCa risk. Colocalization analyses identified strong evidence (posterior probability (PPA) = 81.3%) of a shared genetic variant (rs553741) between liver-derived PCSK9 expression and PrCa risk, whereas weak evidence was found for HMGCR (PPA = 0.33%) and NPC1L1 expression (PPA = 0.38%). Moreover, genetically proxied PCSK9 inhibition was strongly associated with Lp(a) levels (Beta = -0.08, 95% CI = -0.12 to -0.05, P = 1.00 × 10-5), but not BMI or testosterone, indicating a possible role for Lp(a) in the biological mechanism underlying the association between PCSK9 and PrCa. Notably, we emphasise that our estimates are based on a lifelong exposure that makes direct comparisons with trial results challenging. CONCLUSIONS: Our study supports a strong association between genetically proxied inhibition of PCSK9 and a lower risk of total and early-onset PrCa, potentially through an alternative mechanism other than the on-target effect on LDL-c. Further evidence from clinical studies is needed to confirm this finding as well as the putative mediatory role of Lp(a).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Fang S, Yarmolinsky J, Gill D, et al. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS Med. 2023. PMID: 36595504. doi:10.1371/journal.pmed.1003988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。